Neoadjuvant chemotherapy for hypopharyngeal carcinoma

Masato Fujii, Tatsuo Matsunaga, Koichi Tsunoda, Kunio Mizutari, Ryoiti Fujii, Kanako Masuda, Satoko Kimura, Toshiki Tomita, Hiroyuki Ozawa, Takekatsu Fujimine

Research output: Contribution to journalArticle

Abstract

The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.

Original languageEnglish
Pages (from-to)363-368
Number of pages6
JournalToukeibu Gan
Volume31
Issue number3
DOIs
Publication statusPublished - 2005

Fingerprint

Carcinoma
Drug Therapy
docetaxel
Hypopharynx
Survival
Head and Neck Neoplasms
Larynx
Combination Drug Therapy
Fluorouracil
Neck
Radiotherapy
Survival Rate
Head
Carcinoma, squamous cell of head and neck

Keywords

  • combination chemotherapy
  • hypopharyngeal carcinoma
  • neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Oncology

Cite this

Fujii, M., Matsunaga, T., Tsunoda, K., Mizutari, K., Fujii, R., Masuda, K., ... Fujimine, T. (2005). Neoadjuvant chemotherapy for hypopharyngeal carcinoma. Toukeibu Gan, 31(3), 363-368. https://doi.org/10.5981/jjhnc.31.363

Neoadjuvant chemotherapy for hypopharyngeal carcinoma. / Fujii, Masato; Matsunaga, Tatsuo; Tsunoda, Koichi; Mizutari, Kunio; Fujii, Ryoiti; Masuda, Kanako; Kimura, Satoko; Tomita, Toshiki; Ozawa, Hiroyuki; Fujimine, Takekatsu.

In: Toukeibu Gan, Vol. 31, No. 3, 2005, p. 363-368.

Research output: Contribution to journalArticle

Fujii, M, Matsunaga, T, Tsunoda, K, Mizutari, K, Fujii, R, Masuda, K, Kimura, S, Tomita, T, Ozawa, H & Fujimine, T 2005, 'Neoadjuvant chemotherapy for hypopharyngeal carcinoma', Toukeibu Gan, vol. 31, no. 3, pp. 363-368. https://doi.org/10.5981/jjhnc.31.363
Fujii M, Matsunaga T, Tsunoda K, Mizutari K, Fujii R, Masuda K et al. Neoadjuvant chemotherapy for hypopharyngeal carcinoma. Toukeibu Gan. 2005;31(3):363-368. https://doi.org/10.5981/jjhnc.31.363
Fujii, Masato ; Matsunaga, Tatsuo ; Tsunoda, Koichi ; Mizutari, Kunio ; Fujii, Ryoiti ; Masuda, Kanako ; Kimura, Satoko ; Tomita, Toshiki ; Ozawa, Hiroyuki ; Fujimine, Takekatsu. / Neoadjuvant chemotherapy for hypopharyngeal carcinoma. In: Toukeibu Gan. 2005 ; Vol. 31, No. 3. pp. 363-368.
@article{e1a9f25780d245329f23183e43626f25,
title = "Neoadjuvant chemotherapy for hypopharyngeal carcinoma",
abstract = "The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5{\%} for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4{\%}. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.",
keywords = "combination chemotherapy, hypopharyngeal carcinoma, neoadjuvant chemotherapy",
author = "Masato Fujii and Tatsuo Matsunaga and Koichi Tsunoda and Kunio Mizutari and Ryoiti Fujii and Kanako Masuda and Satoko Kimura and Toshiki Tomita and Hiroyuki Ozawa and Takekatsu Fujimine",
year = "2005",
doi = "10.5981/jjhnc.31.363",
language = "English",
volume = "31",
pages = "363--368",
journal = "Japanese Journal of Head and Neck Cancer",
issn = "1349-5747",
publisher = "Nihon Tokeibu Gan Gakkai",
number = "3",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for hypopharyngeal carcinoma

AU - Fujii, Masato

AU - Matsunaga, Tatsuo

AU - Tsunoda, Koichi

AU - Mizutari, Kunio

AU - Fujii, Ryoiti

AU - Masuda, Kanako

AU - Kimura, Satoko

AU - Tomita, Toshiki

AU - Ozawa, Hiroyuki

AU - Fujimine, Takekatsu

PY - 2005

Y1 - 2005

N2 - The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.

AB - The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.

KW - combination chemotherapy

KW - hypopharyngeal carcinoma

KW - neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85009592456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009592456&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.31.363

DO - 10.5981/jjhnc.31.363

M3 - Article

AN - SCOPUS:85009592456

VL - 31

SP - 363

EP - 368

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 3

ER -